Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis by Popivanova Boryana K. et al.
Blocking TNF-α in mice reduces colorectal
carcinogenesis associated with chronic colitis
著者 Popivanova Boryana K., Kitamura Kazuya, Wu Yu,
Kondo Toshikazu, Kagaya Takashi, Kaneko











560	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 118	 	 	 Number 2	 	 	 February 2008
Blocking TNF-α in mice reduces colorectal 
carcinogenesis associated with chronic colitis
Boryana K. Popivanova,1 Kazuya Kitamura,2 Yu Wu,1 Toshikazu Kondo,3 Takashi Kagaya,2  
Shiuchi Kaneko,2 Masanobu Oshima,4 Chifumi Fujii,1 and Naofumi Mukaida1
1Division of Molecular Bioregulation, Cancer Research Institute, and 2Department of Disease Control and Homeostasis, Graduate School of Medical Science, 
Kanazawa University, Kanazawa, Japan. 3Department of Legal Medicine, Wakayama Medical University, Wakayama, Japan. 4Division of Genetics,  

















Ulcerative colitis (UC) is an inflammatory bowel disease character-
ized by pathological mucosal damage and ulceration, which can 
involve the rectum and extend proximally (1). The incidence of 
UC in the United States is about 4–12 per 100,000 and has risen 
in recent decades. UC typically presents as a relapsing disorder 
marked by attacks of bloody mucoid diarrhea that sometimes 
persists for months, only to recur after an asymptomatic interval 
of months to years (1). UC consistently manifests DNA damage 
with microsatellite instability in mucosal cells (2). Thus, repetitive 
relapses and remissions can frequently cause epithelial dysplasia 
and can eventually progress to invasive cancer (3). Indeed, involve-
ment of the entire colon for longer than 10 years predisposes UC 
patients to colon cancer, and the risk of cancer is 20- to 30-fold 
higher in these patients than in a control population (4). Thus, it 
is desirable to develop measures to prevent cancer development 
in UC patients based on an understanding of the pathogenesis of 
colon carcinogenesis in UC at molecular and cellular levels.
Oral administration of dextran sulfate sodium (DSS) solution 
to rodents is widely employed to recapitulate human UC, because 
it can cause acute inflammatory reaction and ulceration in the 
entire colon similar to that observed in UC patients (5). Moreover, 
repeated oral DSS ingestion alone can cause colon carcinoma in 
a proportion of mice when the ingestion is of 7 days’ duration 
and is repeated 9 times (6). These observations suggest that the 
inflammatory response alone can cause colon carcinoma. Azoxy-
methane (AOM) is also frequently used to induce tumors in the 
distal colon of rodents by causing O6-methyl-guanine formation 
(7). A prior administration of AOM can accelerate and increase the 
incidence of DSS-induced colon carcinogenesis, as evidenced by 
the very high incidence of colon cancer (nearly 100%) after 3 subse-
quent rounds of DSS ingestion (8). Inactivation of the IκB/NF-κB 
pathway has been associated with reducing colon carcinogenesis 
induced by the combined treatment of AOM and DSS (9). This 
observation may mirror the enhanced NF-κB activation seen in 
human colon adenoma and cancer tissues (10, 11). This suggests 
that induction of NF-κB by inflammatory stimuli may participate 
in colon carcinogenesis. However, it still remains to be determined, 
which molecule(s), if any, aberrantly enhances NF-κB activation 
during the course of colon carcinogenesis.
NF-κB activation is required for the expression of many pro-
inflammatory molecules including cytokines and adhesion mol-
ecules (12). Among these cytokines, TNF-α can further augment 
NF-κB activation in various cell types after binding to either TNF 
receptor p55 (TNF-Rp55) or TNF-Rp75 (13). Since TNF-Rp55 is 
widely expressed on almost all cell types except erythrocytes (14), 
TNF-Rp55 deficiency has profound effects on endotoxin shock 
(15) and the skin wound healing process (16). TNF-α was origi-
nally identified as a mediator responsible for endotoxin-induced 
tumor necrosis (17) and was utilized for the treatment of patients 
with advanced localized solid tumors (18). On the contrary, we 
observed that liver and lung metastasis were depressed in TNF-
Rp55–deficient (TNF-Rp55–/–) mice (19, 20), suggesting a crucial 
contribution of the TNF-α/TNF-Rp55 axis to the development 
of metastasis. Moreover, TNF-α–deficient mice developed fewer 
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tumors than WT mice when exposed to several types of carcino-
gens (21). Thus, the TNF-α/TNF-Rp55 axis may actually promote 
carcinogenesis and its progression.
Here we investigated the roles of the TNF-α/TNF-Rp55 axis in 
colon carcinogenesis induced by the combined treatment with 
AOM and DSS by utilizing TNF-Rp55–/– mice and a human TNF-
specific antagonist, etanercept, which can block mouse TNF-α 
activities (22). Our experiments revealed that the combined treat-
ment with AOM and DSS induced the intracolonic expression of 
TNF-α, which in turn regulated the trafficking of inflammatory 
cells, a major source of COX-2, thereby resulting in the develop-
ment and progression of colon cancer.
Results
Enhanced TNF expression in the colon during the course of colon carcinogen-
esis. Consistent with previous reports (8, 9), a single intraperitoneal 
injection of the carcinogen AOM, followed by 3 rounds of 2% 
DSS intake induced the development of multiple tumors in 
the middle to distal colon of WT mice (Figure 1, B and C). 
The essential involvement of a transcription factor, NF-κB, in this 
colon carcinogenesis model (9) prompted us to investigate the 
intracolonic expression of TNF-α and its receptor because TNF-α 
is a potent activator of NF-κB (13, 14). TNF-α mRNA was faintly 
expressed in untreated WT mice, and AOM treatment alone did 
not enhance TNF-α mRNA expression, but subsequent DSS intake 
augmented TNF-α mRNA expression (Figure 1D). We also detected 
TNF-α protein expression by immunohistochemical analysis 
mainly in mononuclear cells present in lamina propria and sub-
mucosal regions (Figure 1E). Similarly, immunoreactive TNF-α 
protein was detected in the colons of patients with active UC and 
advanced colorectal cancer, but not in normal mucosa (Supple-
mental Figure 1; supplemental material available online with 
this article; doi:10.1172/JCI32453DS1). Immunohistochemical 
analysis detected the major receptor for TNF-α, TNF-Rp55, pre-
dominantly in leukocytes infiltrating the lamina propria and 
submucosal regions of the colon during the course of this colon 
carcinogenesis model (Figure 1F).
Reduced tumor incidence in TNF-Rp55–/– mice. In order to clarify the 
role of TNF-Rp55 in this colon carcinogenesis model, we treated 
both WT and TNF-Rp55–/– mice with AOM and DSS in the same 
manner. During the course of AOM and DSS treatment, WT mice 
exhibited profound body weight loss and bloody diarrhea, where-
as TNF-Rp55–/– mice had less body weight loss and did not have 
bloody diarrhea (data not shown). There were no apparent differ-
ences in macroscopical and microscopical appearance of the colon 
of untreated WT and TNF-Rp55–/– mice (Figure 2A). In treated WT 
mice, edema and hyperemia of the middle to distal colon became 
evident after day 7, and multiple tumors developed in the same 
region after day 28, whereas these morphological changes were rare 
in AOM and DSS–treated TNF-Rp55–/– mice (data not shown). His-
tological analysis consistently demonstrated massive infiltration 
of leukocytes into the mucosa and edema of the submucosa, with 
loss of entire crypts and surface epithelium by day 7, particularly 
in the middle to distal colon of WT mice (Figure 2A). At day 14, 
mucosal inflammatory cell infiltration persisted and was accom-
panied by dysplastic glands with hyperchromatic nuclei, decreased 
mucin production, and dystrophic goblet cells. By days 28 to 35, 
macroscopically visible adenocarcinomatous lesions developed, 
and their size and numbers increased progressively thereafter. 
Moreover, β-catenin accumulated in the nuclei of the tumor cells 
after day 28 (Figure 2B). On the contrary, TNF-Rp55–/– mice dis-
played much milder inflammation of the colon during the course 
of DSS intake and developed fewer adenocarcinomatous lesions 
and less nuclear β-catenin accumulation (Figure 1C and Figure 2, 
Figure 1
Tumor formation in WT and TNF-Rp55–/– (TNF-
Rp55KO) mice after AOM and DSS treatment. 
(A) Schematic overview of this colon carcinogen-
esis model. (B) Macroscopical changes in colon. 
Colons were removed at day 56 from treated WT 
and TNF-Rp55–/– mice, and representative results 
from 10 independent animals are shown here. (C) 
The numbers of tumors. Colons were removed at 
day 56 to determine the numbers of macroscopic 
tumors. Each value represents the mean ± SD 
(n = 10 animals). **P < 0.01 versus WT. (D). TNF-α 
gene expression in the colons of WT mice. The 
levels of TNF-α mRNA were quantified by quanti-
tative RT-PCR as described in Methods, and nor-
malized to the level of GAPDH mRNA. *P < 0.05, 
**P < 0.01 versus untreated (control) mice. (E and 
F) Immunohistochemical detection of TNF-α and 
TNF-Rp55 in colons. Colons were obtained from 
WT mice at the indicated time intervals; insets are 
higher magnification of the positively stained cells 
as indicated by arrows. Representative results from 
6 independent experiments are shown here (original 
magnification, ×400; ×1,000 [insets]).
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A and B). Moreover, the numbers of apoptotic cells were transiently 
increased at day 7 in WT but not TNF-Rp55–/– mice, as revealed by 
TUNEL assay (Supplemental Figure 2). However, the incidence of 
apoptotic cells detected in TNF-Rp55–/– mice was similar in level to 
those in WT mice except on day 7 (Supplemental Figure 2). These 
observations suggest a crucial role in this model for TNF-Rp55–
mediated signals in the development of chronic inflammation and 
colon carcinoma but not in the apoptotic reactions.
Figure 2
Microscopical analysis of colon tissues. (A) Colons were removed at the indicated time intervals, fixed, and stained with hematoxylin and eosin. 
Representative results from 5 mice are shown here. Original magnification, ×200. (B) Immunohistochemical staining for β-catenin. Colons were 
removed at the indicated time intervals from WT and TNF-Rp55–/– (TNF-Rp55KO) mice and immunostained with anti–β-catenin antibody as 
described in Methods. Boxed areas in the left panels are shown at higher magnification in the middle panels. Representative results from 3 
independent animals are shown here. Original magnification, ×400 (top and bottom rows), ×1,000 (middle row). (C–G) The numbers of myelo-
peroxidase- (C), F4/80- (D), CD4- (E), CD8- (F), and DEC205-positive cells (G) were counted as described in Methods and are shown here. All 
values represent the mean ± SD (n = 10 animals). *P < 0.05, **P < 0.01 versus untreated (control) WT mice.
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Inflammatory cell infiltration. We next proceeded to identify the 
types of cells that were decreased in the absence of TNF-Rp55 by 
immunohistochemical analysis. In treated WT mice, neutrophils 
and macrophages infiltrated into lamina propria and submucosa 
after day 7 and persisted until day 56 (Supplemental Figure 3). 
In addition, after day 7 aggregates of CD4-positive lymphocytes 
and DEC205-positive dendritic cells infiltrated into the lamina 
propria and submucosa (Supplemental Figure 3). In AOM and 
DSS–treated TNF-Rp55–/– mice, infiltration by both neutrophils 
and macrophages was markedly decreased, whereas lymphocyte 
and dendritic cell infiltration was minimally affected (Figure 2, 
C–G). TNF-α can augment the expression of the chemokines 
keratinocyte chemoattractant/CXCL1 (KC/CXCL1) and mono-
cyte chemoattractant protein–1/CCL2 (MCP-1/CCL2), which 
are chemotactic for neutrophils and macrophages, respectively 
(23, 24). Indeed, after day 7, gene expression of both chemokines 
was enhanced in WT mice, but their expression was consistently 
depressed in TNF-Rp55–/– mice (Figure 3). These observations 
suggest that TNF-Rp55–mediated signals were responsible for 
the trafficking of neutrophils and macrophages, at least in part by 
enhancing the expression of chemokines. Moreover, it is plausible 
that bone marrow–derived cells, neutrophils and macrophages, 
can be crucially involved in this colon carcinogenesis model. In 
order to address the contribution of bone marrow–derived cells, 
we treated various bone marrow chimeric mice with the same com-
bination of AOM and DSS. TNF-Rp55–/– mice transplanted with 
WT-derived bone marrow cells developed tumors at a similar level 
as WT mice transplanted with WT-derived bone marrow cells, but 
at a higher level than either WT or TNF-Rp55–/– mice transplanted 
with TNF-Rp55–/– mouse–derived bone marrow cells (Figure 4). 
These observations suggest that TNF-Rp55–mediated signals act 
mainly on bone marrow, but not non–bone marrow–derived cells 
in this carcinogenesis model.
Reduced COX-2 expression in TNF-Rp55–/– mice. Accumulating evi-
dence indicates the causal involvement of COX-2 in colon carcino-
genesis. Hence, we examined COX-2 mRNA expression by real-time 
RT-PCR. After day 7, intracolonic COX-2 expression was markedly 
enhanced in treated WT but not TNF-Rp55–/– mice (Figure 5A). 
COX-2 protein was detected mainly in infiltrating inflamma-
tory cells (Figure 5B), and the numbers of COX-2–positive cells 
increased from day 7 to day 56 in WT but not TNF-Rp55–/– mice 
(Figure 5, B and C). Double-color immunofluorescence analysis 
detected COX-2 protein in F4/80-positive macrophages and to 
a lesser extent in Ly-6G–positive neutrophils (Figure 5D). These 
observations suggest that in the absence of TNF-Rp55 the infiltra-
tion of macrophages and neutrophils, which are a major source of 
COX-2, was reduced, leading to decreased COX-2 expression.
Effect of TNF-α antagonist, etanercept, on tumor formation in WT mice. 
Because the human TNF antagonist, etanercept, can inhibit the 
biological activity of murine TNF (22), we explored its effects on 
tumor progression by administering it to mice from day 56 to day 
60, after the AOM and 3 cycles of DSS treatments (Figure 6A). Com-
pared with the vehicle-treated group, etanercept treatment reduced 
the numbers and size of macroscopical tumors remarkably when 
administered even over this short and delayed time period (Figure 
6, B–D). Concomitantly, etanercept treatment reduced intraco-
lonic infiltration by inflammatory cells, particularly neutrophils 
and macrophages (Figure 6, E and F, and Supplemental Figure 4), 
Figure 3
Chemokine gene expression in the colons. Quantitative RT-PCR was 
performed on total RNAs extracted from the colons at the indicated 
time intervals as described in Methods. The levels of KC/CXCL1 (A) 
and MCP-1/CCL2 (B) mRNA were normalized to GAPDH mRNA lev-
els. Representative results from 5 independent experiments are shown 
in here. *P < 0.05, **P < 0.01 versus untreated (control) mice.
Figure 4
Colon tumor formation in bone marrow chimeric mice. Bone marrow 
chimeric mice were generated and subjected to AOM+DSS treatment 
as described in Methods. Colons were removed at day 56, and the 
tumor numbers were determined macroscopically. The bars represent 
the median of each group; each symbol represents the tumor numbers 
of each animal. **P < 0.01.
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together with a decrease in mRNA levels of the neutrophil-tropic 
chemokine, KC/CXCL1, and the macrophage-tropic chemokine, 
MCP-1/CCL2 (Figure 6, G and H). Furthermore, etanercept reduced 
COX-2 mRNA expression (Figure 7A) and the numbers of COX-2 
expressing cells (Figure 7, B and C). Because COX-2–derived PGE2 is 
an important stimulant of tumor angiogenesis (25), we next exam-
ined the effect of etanercept on the intratumoral vascular density by 
immunostaining with anti-CD31 antibody. At 56 and 67 days after 
the initiation of DSS intake, WT mice exhibited a marked increase 
in vascular densities, and this increment was markedly depressed by 
etanercept (Figure 7, D and E).
PGE2 has also been reported to have direct effects on the 
β-catenin axis (26). This prompted us to evaluate the state of 
β-catenin in the tumors of mice treated with etanercept. Indeed, 
etanercept also decreased the nuclear accumulation of β-catenin 
at the tumor sites (Figure 8, A and B). The amounts of unphos-
phorylated (active) β-catenin protein were increased in WT mice 
at days 56 and 67, and etanercept markedly reduced this increase 
(Figure 8C). Moreover, etanercept markedly decreased the num-
bers of cytokeratin 20–positive cells (Figure 8, A and D), which 
represent colon adenocarcinoma cells (27). Takahashi and col-
leagues observed that in these AOM-induced tumors, the β-catenin 
Figure 5
COX-2 expression in the colons. (A) Quantitative RT-PCR was performed on total RNAs extracted from the colons at the indicated time intervals 
as described in Methods. The levels of COX-2 mRNA were normalized to the levels of GAPDH mRNA. **P < 0.01 versus untreated (control) 
mice. (B–D) Immunohistochemical and immunofluorescence detection of COX-2–expressing cells. Colons were obtained from WT mice at the 
indicated time intervals and processed for immunohistochemical analysis using anti–COX-2 antibodies, and representative results from 5 inde-
pendent animals are shown in B. The numbers of COX-2–expressing cells were determined as described in Methods and are shown in C and 
expressed as mean ± SD. *P < 0.05, **P < 0.01 versus untreated. Double-color immunofluorescence analysis was performed with the combina-
tion of anti–COX-2 and anti–F4/80 (D, top row) or that of anti–COX-2 and anti-Ly6G antibodies (D, bottom row). Representative results from 5 
independent experiments are shown here. Original magnification, ×400 (B); ×800 (D). Scale bars, 10 μm.
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gene, particularly at its glycogen synthase kinase–3β (GSK-3β) 
phosphorylation sites, mutated more frequently than adenoma-
tous polyposis coli (APC) gene (28). Hence, we examined the effects 
of TNF blockade on the mutations of the GSK-3β phosphoryla-
tion sites of the β-catenin gene, located in its exon 3. Mutations of 
β-catenin gene were detected in all tumors, and etanercept treat-
ment reduced the mutation frequency markedly from 10/10 posi-
tive in the untreated group to 3/10 in the etanercept-treated group 
(Supplemental Table 1). These observations suggest that blocking 
of TNF signaling can reverse tumorigenesis even when colon car-
cinoma is already present, probably by reducing the infiltration of 
inflammatory cells. Such cells are a major source of COX-2, which 
is presumed to be involved in both tumor neovascularization and 
β-catenin activation.
Discussion
During relapses acute attacks of UC cause a massive infiltration 
of neutrophils and mononuclear cells into the lamina propria and 
ulceration of colon extending into the submucosa. During remis-
sions of active disease, granulation tissues fill the ulcer craters, 
accompanied by regeneration of the mucosal epithelium (1, 29). 
Aminosalicylates, corticosteroids, and cyclosporine are all used to 
induce remissions and prevent relapse of quiescent disease (29). 
Despite these medical treatments, UC patients frequently experi-
ence relapses and sometimes undergo colectomy. Moreover, recur-
rent relapses can cause dysplasia of regenerated mucosal epithelium 
and subsequent progression to frank carcinoma (2, 3). Accordingly, 
new treatments for UC are needed. A recent clinical trial demon-
strated that humanized anti–TNF-α antibody was beneficial for the 
treatment of moderately to severely active UC patients (30). How-
ever, the pathogenic role of TNF-α in UC remains unclear and is 
particularly so in UC-associated colon carcinogenesis. Hence, we 
examined the process of chronic colitis–induced colon carcino-
genesis by using mice deficient in TNF-Rp55, a major receptor for 
TNF-α as well as a TNF antagonist, and demonstrated the critical 
role of the TNF signaling pathway in colon carcinogenesis.
Greten and colleagues have revealed the crucial involvement of 
the IκB kinase β/NF-κB (IKKβ/NF-κB) in colon carcinogenesis 
induced by combined treatment with AOM and DSS (9). They fur-
ther demonstrated that depletion of IKKβ in intestinal epithelial 
cells increased epithelial apoptosis and concomitantly decreased 
tumor incidence without affecting tumor size and inflammation. 
Figure 6
The effects of a TNF antagonist, etanercept, on colon carcinogenesis. (A) Schematic overview of etanercept administration. Colons were 
removed at day 67 after the mice were administered etanercept (Et) or a vehicle control between days 56 and 60. (B) The tumor sizes and 
numbers were determined macroscopically. The bars represent the median of each group. Each symbol represents the tumor numbers of each 
animal or the average size of the tumors of each animal. (C) Macroscopic evaluation of the tumors. Colons were removed on day 67 from WT 
mice, treated with etanercept or with vehicle. Representative results from 10 independent animals are shown here. Original magnification, ×6. 
(D) Colons were processed for hematoxylin and eosin staining and representative results from 5 independent animals are shown here. Original 
magnification, ×40. (E and F) Myeloperoxidase- (E) and F4/80-positive cells (F) were enumerated as described in Methods. All values repre-
sent the mean ± SD (n = 10 animals). *P < 0.05, **P < 0.01 versus etanercept-untreated WT mice. (G and H) Quantitative RT-PCR analysis 
for KC/CXCL1 (G) and MCP-1/CCL2 (H) was performed on total RNAs extracted from the colons at the indicated time intervals as described in 
Methods. KC/CXCL1 and MCP-1/CCL2 mRNA levels were normalized to the levels of GAPDH mRNA. *P < 0.05, **P < 0.01 versus etanercept 
untreated WT mice.
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In contrast, depleting IKKβ in myeloid cells reduced tumor size 
and inflammation without affecting apoptosis (9). However, in 
our model, epithelial cell apoptosis was transiently increased at day 
7 in WT mice, and this increase was absent in TNF-Rp55–/– mice 
(Supplemental Figure 2). Moreover, in the absence of TNF-Rp55, 
colonic inflammation was reduced as was the tumor incidence 
and size. Furthermore, both TNF-α and TNF-Rp55 were expressed 
mainly by infiltrating cells but not epithelial cells. Thus, it is plau-
sible to speculate that endogenously produced TNF-α activated 
NF-κB in inflammatory cells by interacting with TNF-Rp55 in an 
autocrine/paracrine manner, and caused extensive colonic inflam-
mation, thereby inducing carcinogenesis in this model.
In most cases of colon carcinogenesis, the earliest event is the loss 
of the APC gene, resulting in nuclear β-catenin accumulation (31), 
as we observed in tumor tissues in this study. Carcinoma progres-
sion occurs due to chromosomal 
instability, which results in a step-
wise accumulation of mutations in 
a number of oncogenes and tumor 
suppressor genes. TNF-α has been 
proposed to be a potent mutagen 
based on its capacity to induce the 
generation of ROS and subsequent 
genetic instability in various types 
of cells (32, 33). This assumption 
may be further corroborated by the 
observations that the incidence of 
chemically induced skin carcinomas 
was markedly reduced in TNF-α– 
deficient mice (21) or by the admin-
istration of neutralizing antibody 
to TNF-α (34). Thus, blocking of 
TNF activities may prevent ROS 
generation, thereby dampening the 
initiation of colon carcinogenesis 
in our model.
The progression to invasive can-
cer requires the induction of tumor 
vasculature, termed the angiogenic 
switch (35). Given the angiogenic 
activities of TNF-α (36, 37), block-
ing of TNF signals may prevent the 
angiogenic switch as evidenced by 
reduced tumor neovascularization 
with etanercept administration. 
Moreover, several lines of evidence 
implied that infiltrating macro-
phages and/or neutrophils had a 
crucial role in the angiogenic switch 
(38, 39). We observed that macro-
phages and neutrophils infiltrated 
into tumor tissues, exhibiting 
enhanced expression of chemo-
kines active for macrophages and 
neutrophils, and that blocking of 
TNF signals reduced macrophage 
and neutrophil infiltration, togeth-
er with reduced chemokine gene 
expression and tumor neovascular-
ization. Furthermore, some of these 
chemokines can also enhance endothelial cell proliferation (40). 
Because TNF-α can induce the expression of these chemokines in 
vitro and in vivo (23, 24), the TNF-α/TNF receptor axis may regu-
late the angiogenic switch directly or indirectly by inducing the 
expression of chemokines, which can induce both the prolifera-
tion of endothelial cells and the infiltration of inflammatory cells, 
another rich source of angiogenic factors.
Epidemiological studies demonstrated that nonsteroidal anti-
inflammatory drugs (NSAIDs) are effective in reducing the inci-
dence of colon cancer (41, 42). NSAIDs can inhibit the enzymatic 
activities of both COX-1 and COX-2, but only COX-2 expression 
was enhanced in colon carcinoma tissues (43). Moreover, COX-2 
gene ablation or the administration of a selective COX-2 inhibi-
tor suppressed the intestinal polyposis observed in APC-deficient 
mice (44). COX-2 converts arachidonic acid to PGH2, which is 
Figure 7
The effect of etanercept on COX-2 expression and angiogenesis. (A) Quantitative RT-PCR analysis 
for COX-2 was performed on total RNAs extracted from the colons at the indicated time intervals as 
described in Methods. The levels of COX-2 mRNA were normalized to the levels of GAPDH mRNA. 
*P < 0.05 versus untreated (control) mice. (B and C) Immunohistochemical analysis with anti–COX-2 
antibody was performed on colons from WT mice as described in Methods. Boxed area in B is shown 
at higher magnification. Representative results from 5 independent animals are shown in B (original 
magnification, ×400; ×1,000 [insets]). The numbers of COX-2 expressing cells were determined on 5 
independent animals as described in Methods. The mean and SD were calculated on all values and 
are shown in C. *P < 0.05 versus untreated mice. (D and E) Colon tissues were immunostained with 
anti-CD31 antibody as described in Methods. Representative results from 5 independent animals are 
shown in D. Arrows in D indicate capillary vessels. Original magnification, ×400. The vascular densities 
were determined as described in Methods and are shown in E. All values represent the mean ± SD. 
*P < 0.05 versus untreated mice.
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further converted to other PGs including PGE2 and thrombox-
anes (25). Several lines of evidence implicate PGE2 as an essential 
mediator for angiogenesis in colon carcinogenesis (25, 45–47). 
In our model, we also observed that COX-2 mRNA expression 
was enhanced by DSS ingestion and that COX-2 proteins were 
detected in F4/80-positive macrophages and Ly-6G–positive neu-
trophils, similar to what has been observed in human and mouse 
colon cancer tissues (43, 48, 49). Moreover, TNF-Rp55 gene abla-
tion and TNF antagonist administration reduced both COX-2 
expression and tumor angiogenesis. Thus, TNF may also enhance 
tumor angiogenesis by inducing the infiltration of COX-2– 
expressing macrophages and neutrophils.
Accumulating evidence suggests that PGE2 has direct effects 
in enhancing colonic epithelial cell survival. PGE2 transactivated 
nuclear peroxisome proliferator–activated receptor δ through 
PI3K/Akt signaling, resulting in promoted cell survival and intesti-
nal adenoma formation (50). Moreover, PGE2 transactivated hepa-
tocyte growth factor (HGF) receptor and induced urokinase-type 
plasminogen activator receptor mRNA, thereby enhancing colon 
cancer cell invasive capacity (51). It is of interest that PGE2-induced 
HGF receptor transactivation also induced nuclear translocation 
of β-catenin (51), suggesting a connection between PGE2 and the 
Wnt/β-catenin axis. Supporting this notion, upon binding to its 
specific receptor, EP2, PGE2 activated the Wnt/β-catenin axis in 
colon cancer cells through the phosphoinositide 3–kinase/Akt-G 
protein αs-axin signaling axis resulting in the promotion of cell 
growth (26). Moreover, PGE2 increased the phosphorylation of 
GSK-3 and induced the accumulation of β-catenin and the expres-
sion of its transcription partner, T cell factor–4, thereby inducing 
the β-catenin/T cell factor-dependent gene transcription in colon 
cancer cells (52). Thus, COX-2–derived PGE2 can directly regulate 
colon carcinogenesis by regulating Wnt signaling pathway, which 
has a crucial role in colon carcinogenesis. We observed, on the 
other hand, that etanercept consistently reduced COX-2 expres-
sion and the amount of nuclear β-catenin as well as neovascular-
ization, even when it was administered after macroscopic tumor 
formation. Therefore, TNF blocking may retard the progression 
of colon carcinomas by reducing COX-2 expression and eventually 
inhibiting the Wnt signaling pathway.
Our present observations have revealed the crucial involvement of 
TNF-α in the initiation of chronic inflammation-mediated colon 
carcinogenesis. Moreover, blocking of TNF-α reversed carcinoma 
progression, even after colon carcinoma was established. TNF-α 
blocking agents can have serious adverse effects including the 
induction of bacterial, tuberculosis, and opportunistic infections, 
but the incidence is low (30, 53). Thus, drugs targeting TNF-α 
may be useful for the treatment of cancers, particularly those aris-
ing from chronic inflammation.
Methods
Reagents and antibodies. AOM and DSS (MW 36,000–50,000) were purchased 
from Sigma-Aldrich and MP Biochemicals Inc., respectively. A specific 
Figure 8
The effect of etanercept on β-catenin nuclear translocation. (A) Colons were immunostained with anti–β-catenin (upper panels) or anti–cytokera-
tin 20 antibody (lower panels) and representative results from 5 independent animals are shown. Insets are higher magnifications of the positively 
stained cells, indicated by arrows. Original magnification, ×400; ×1,000 (insets). (B) The β-catenin nuclear localization ratio was determined as 
the ratio of the numbers of tumor nuclei with β-catenin localization to the total number of tumor nuclei per field. At least 5 randomly chosen fields 
at ×400 magnification were examined. All values represent the mean ± SD. **P < 0.01 versus etanercept untreated WT mice. (C) Immunoblotting 
analysis with anti–β-catenin antibodies was performed on cell lysates from colon tissues as described in Methods. Representative results from 3 
independent experiments are shown here. (D) The numbers of cytokeratin 20–positive cells were determined on 5 randomly chosen visual fields 
at ×400 magnification. All values represent the mean ± SD. **P < 0.01 versus etanercept untreated WT mice.
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TNF antagonist, etanercept, was purchased from Wyeth Pharmaceutical 
Japan. Rat anti-F4/80, rat anti-CD3, and rat anti-DEC205 antibodies were 
obtained from Serotec. Goat anti–COX-2 antibodies and rabbit anti-myelo-
peroxidase antibodies were obtained from Santa Cruz Biotechnology and 
Neomarkers, respectively. Rabbit anti−β-catenin, anti–active β-catenin, and 
rabbit anti–α/β-tubulin antibodies were from Sigma-Aldrich, Upstate, and 
Cell Signaling Technology Inc., respectively. Rabbit polyclonal anti–TNF-
Rp55, mouse monoclonal anti-human TNF-α, rabbit polyclonal anti-
CD31, and mouse monoclonal antibody to cytokeratin 20 were obtained 
from Abcam. Rabbit polyclonal anti–TNF-α antibody was prepared by 
immunizing rabbits with a recombinant mouse TNF-α protein (54). 
ImmunoPure peroxidase-conjugated goat anti-mouse and goat anti-rab-
bit antibodies were obtained from Pierce Biotechnology Inc. Alexa Fluor 
546 donkey anti-goat and Alexa Fluor 488 donkey anti-rat antibodies were 
obtained from Molecular Probes. Other antibodies were obtained from BD 
Bioscience – Pharmingen unless otherwise indicated.
Animal experiments. Pathogen-free 8- to 12-week old female WT BALB/c 
mice and TNF-Rp55–/– mice on a BALB/c genetic background, were housed 
under specific pathogen-free conditions with free access to food and 
water during the course of experiments (16, 19, 20). Mice were injected 
intraperitoneally with 12 mg/kg body weight of AOM dissolved in physi-
ological saline. Five days later, 2% DSS was given in the drinking water 
over 5 days, followed by 16 days of regular water. This cycle was repeated a 
total of 3 times (Figure 1A). Body weight was measured every week, and the 
animals were sacrificed at the indicated time intervals for macroscopical 
inspection, histological analysis, and total RNA extraction. In some experi-
ments, WT mice were injected with etanercept at a dose of 3 mg/kg body 
weight every day from day 56 to day 60 (Figure 6A). All animal experiments 
were approved by the Committee on Animal Experimentation of Kanazawa 
University and performed in compliance with the university’s Guidelines 
for the Care and Use of Laboratory Animals.
Bone marrow chimeric mice generation. Cell suspensions from male WT or 
TNF-Rp55–/– bone marrow were prepared from femurs and tibias, filtered, 
and counted. Female WT or TNF-Rp55–/– mice received a single intrave-
nous injection of 1 × 107 bone marrow cells, after being irradiated with 
8.5-Gy followed by 4.25-Gy x-rays (MPR-1520R; Hitachi) 4 hours later. 
The following groups of chimeric mice were generated: WT to WT, WT to 
TNF-Rp55–/–, TNF-Rp55–/– to WT, and TNF-Rp55–/– to TNF-Rp55–/– mice. 
Genomic DNA was extracted from blood, and bone marrow chimerism was 
determined 4 weeks later by PCR for the Y chromosome–linked Sry gene 
(forward, 5′-TGGGACTGGTGACAATTGTC-3′; reverse, 5′-GAGTACAG-
GTGTGCAGCTCT-3′).
Histopathological and immunohistochemical analyses of mouse colon tissues. 
Resected mouse colon tissues were fixed in 10% formalin neutral buffer 
solution (Wako) for paraffin embedding or were immediately frozen in 
Tissue-Tek O.C.T. compound (Sakura Fine Technical Co.) and stored at 
–80°C. Paraffin-embedded sections were cut at 5 μm and stained with 
hematoxylin and eosin solution. Paraffin-embedded sections were addi-
tionally deparaffinized for immunohistochemical detection of cells posi-
tively stained for β-catenin, TNF-Rp55, MPO, F4/80, CD3, CD31, or cyto-
keratin 20. Frozen sections were fixed in 4% paraformaldehyde/PBS for 
15 minutes for immunohistochemical detection of cells positively stained 
for mouse TNF-α, CD4, CD8, or DEC205. Endogenous peroxidase activ-
ity was blocked using 3% H2O2 for 5 minutes, followed by incubation with 
Non-Specific Staining Blocking reagent (DakoCytomation) for 10 min-
utes. The sections were incubated with the optimal dilutions of anti-MPO, 
anti-F4/80, anti-CD3, anti-CD4, anti-CD8, anti-DEC205, anti–β-catenin, 
anti–COX-2, anti-CD31, or anti–cytokeratin 20 antibodies overnight at 
4°C. MPO-, β-catenin-, TNF-α–, TNF-Rp55–, and anti-CD31–positive 
cells were detected with HRP-labeled anti-rabbit polymer (EnVision+ Sys-
tem; DakoCytomation), while F4/80- and CD3-positive cells were detected 
using Catalyzed Signal Amplification (CSA) System (DakoCytomation). 
Immune complexes were visualized with Peroxidase Substrate DAB kit 
(Vector Laboratories Inc.). CD4-, CD8-, DEC205-, and COX-2–positive cells 
were detected by the incubation with anti-rat or anti-goat biotinylated IgG 
(1:200; DakoCytomation). Detection of cytokeratin 20 was performed with 
Vector M.O.M. Immunodetection kit (Vector Laboratories Inc.), which was 
used according to the manufacturer’s instructions. The resultant immune 
complexes were visualized by ABC Elite kit (Vector Laboratories Inc.) and 
Peroxidase Substrate DAB kit (Vector Laboratories Inc.) according to the 
manufacturer’s instructions. Finally, the slides were counterstained with 
hematoxylin, dehydrated, and coverslipped. Positive cells were enumerated 
on 5 randomly chosen visual fields at ×400 magnification. The pixel num-
bers of CD31-positive areas were measured on 5 randomly chosen visual 
fields at ×200 magnification with the aid of Adobe Photoshop software. For 
double-color immunofluorescence analysis, the sections were incubated 
with the combination of anti–COX-2 and anti-F4/80 or with anti–COX-2 
and anti–Ly-6G antibodies at 4°C, overnight. Alexa Fluor 546 donkey anti-
goat and Alexa Fluor 488 donkey anti-rat antibodies were used as second-
ary antibodies. Immunofluorescence was visualized on a Carl Zeiss Laser 
Scanning Microscope 510.
Immunohistochemical detection of TNF-α in human colon tissues. The tissues 
were obtained upon biopsy from patients with UC and colorectal cancer 
with an informed consent and with approval from the Human Subjects 
Research Ethical Committee of Kanazawa University Hospital. The tissues 
were fixed and paraffin-embedded and were cut at 5 μm. Paraffin-embed-
ded sections were additionally deparaffinized for immunohistochemical 
analysis, using the combination of anti-human TNF-α mouse monoclonal 
antibody and CSA system.
TUNEL assay. Paraffin-embedded sections were stained with In situ Apop-
tosis Detection Kit (TaKaRa Bio Inc.), according to the manufacturer’s 
instructions, to detect apoptotic cells. TUNEL-positive cells were counted 
on 5 randomly chosen visual fields at ×400 magnification.
Quantitative RT-PCR. Total RNA was extracted from colon tissues with 
RNA-Bee (Tel-Test Inc.) and 2.5 μg of RNA was reverse-transcribed using 
ReverTraAce (Toyobo) and random primers as described previously. Real-
time PCR was performed on Applied Biosystems StepOne Real-Time 
PCR System (Applied Biosystems) using the comparative Ct quantitation 
method. TaqMan Gene Expression Assays (Applied Biosystems) contain-
ing specific primers (accession numbers: TNF-α–Mm00443258_m1, KC/
CXCL1–Mm00433859_m1, MCP-1/CCL2–Mm00441242_m1, COX-2– 
Mm00478374_m1, GAPDH–Mm99999915_g1), TaqMan MGB probe 
(FAM dye-labeled), and TaqMan Fast Universal PCR Master Mix were used 
with 10 ng of cDNA to detect and quantify the expression levels of TNF-α, 
KC/CXCL1, MCP-1/CCL2, and COX-2 in mouse colon tissues. GAPDH 
was amplified as internal control. Ct values of GAPDH were subtracted 
from Ct values of the target genes (ΔCt). ΔCt values of treated mice were 
compared with ΔCt values of untreated animals. Reactions were done at 
95°C for 20 seconds followed by 40 cycles of 95°C for 1 second and 60°C 
for 20 seconds, 60°C, 20 seconds — 40 cycles.
DNA sequencing and mutation analysis of β-catenin gene. After sequential 
treatment with AOM and DSS, WT mice were injected with either vehicle 
or etanercept every day from day 56 to day 60 (Figure 6A). Tumors were 
obtained at day 67 and embedded in paraffin. Genomic DNA was extracted 
from paraffin-embedded tumor sections by using NucleoSpin Tissue Kit 
(Macherey-Nagel Inc.) according to the manufacturer’s instructions. Exon 3 
of the β-catenin gene, containing the consensus sequence for GSK-3β 
phosphorylation, was amplified by PCR, using specific primers (forward, 
5′-GCTGACCTGATGGAGTTGGA-3′, reverse, 5′-GCTACTTGCTCTTGC-
GTGAA-3′) and the following thermal cycling parameters: 94°C, 5 min-
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utes; followed by 35 cycles at 94°C, 45 seconds, 55°C, 1 minute, and 72°C, 
1 minute; followed by 72°C, 5 minutes. PCR products were subcloned into 
pSTBlue-1 vector (AccepTor vector; Novagen) and sequenced using BigDye 
Terminator Ver. 3.1 Cycle Sequencing kit (Applied Biosystems) on an ABI 
PRISM 3100-Avant Genetic Analyzer (Applied Biosystems).
Immunoblotting analysis. Colon tissues were homogenized and sonicated 
in RIPA lysis buffer (Santa Cruz Biotechnology Inc.), supplemented with 
protease inhibitors. After centrifugation at 20,000 g for 15 minutes, 30 μg of 
the supernatants were separated on 10% SDS-polyacrylamide gel and trans-
ferred onto an Immobilon-P Transfer membrane (Millipore). After being 
blocked with 5% skim milk, the membrane was incubated with antibod-
ies to total β-catenin (1:1,000) and active β-catenin (1:500). Rabbit anti–α/ 
β-tubulin antibody (1:1,000) was used as an internal control. ImmunoPure 
peroxidase-conjugated anti-mouse or anti-rabbit IgG were used as secondary 
antibodies. The blotted membrane was then treated with the Super Signal 
West Dura Extended Duration Substrate (Pierce Biotechnology Inc.) and sig-
nals were detected by LAS-3000 mini CCD camera (Fuji Film).
Statistics. The means ± SD were calculated for all parameters determined. 
Statistical significance was evaluated using 1-way ANOVA, followed by 
Fisher’s protected least significant difference test. P values less than 0.05 
were considered statistically significant.
Acknowledgments
We would like to express our gratitude to Joost J. Oppenheim 
(National Cancer Institute–Frederick) for his critical review and 
editing of the manuscript.
Received for publication April 20, 2007, and accepted in revised 
form November 28, 2007.
Address correspondence to: Naofumi Mukaida, Division of 
Molecular Bioregulation, Cancer Research Institute, Kanazawa 
University, 13-1 Takara-machi, Kanazawa 920-0934, Japan. Phone: 
81-76-265-2767; Fax: 81-76-234-4520; E-mail: naofumim@ 
kenroku.kanazawa-u.ac.jp.
Kazuya Kitamura’s present address is: Mucosal Immunology 
Section, Laboratory of Molecular Immunology, NIAID, NIH, 
Bethesda, Maryland, USA.
Chifumi Fujii’s present address is: Department of Integrative 
Physiology and Biosystem Control, Graduate School of Medicine, 
Shinshu University, Matsumoto, Japan.
 1. Fiocchi, C. 1998. Inflammatory bowel disease: Etiolo-
gy and pathogenesis. Gastroenterology. 115:182–205.
 2. Risques, R.A., Rabinovitch, P.S., and Brentnall, T.A. 
2006. Cancer surveillance in inflammatory bowel 
disease: new molecular approaches. Curr. Opin. Gas-
troenterol. 22:382–390.
 3. Ullman, T., Croog, V., Harpaz, N., Sachar, D., and 
Itzkowitz, S. 2003. Progression of flat low-grade 
dysplasia to advanced neoplasia in patients with 
ulcerative colitis. Gastroenterology. 125:1311–1319.
 4.  Dobbins, W.O., 3rd. 1984. Dysplasia and malig-
nancy in inflammatory bowel disease. Annu. Rev. 
Med. 35:33–48.
 5. Okayasu, I., et al. 1990. A novel method in the 
induction of reliable experimental acute and 
chronic ulcerative colitis in mice. Gastroenterology. 
98:694–702.
 6. Okayasu, I., et al. 2002. Dysplasia and carcinoma 
development in a repeated dextran sulfate sodium-
induced colitis model. J. Gastroenterol. Hepatol. 
17:1078–1083.
 7. Boivin, G.P., et al. 2003. Pathology of mouse mod-
els of intestinal cancer: consensus report and rec-
ommendations. Gastroenterology. 124:762–777.
 8. Okayasu, I., Ohkusa, T., Kajiura, K., Kanno, J., and 
Sakamoto, S. 1996. Promotion of colorectal neo-
plasia in experimental murine ulcerative colitis. 
Gut. 39:87–92.
 9. Greten, F.R., et al. 2004. IKKβ links inflammation 
and tumorigenesis in a mouse model of colitis-
associated cancer. Cell. 118:285–296.
 10. Lind, D.S., et al. 2001. NF-κB is upregulated in 
colorectal cancer. Surgery. 130:363–369.
 11. Hardwick, J.C., van den Brink, G.R., Offerhaus, G.J., 
van Deventer, S.J., and Peppelenbosch, M.P. 2001. 
NF-κB, p38 MAPK and JNK are highly expressed 
and active in the stroma of human colonic adeno-
matous polyps. Oncogene. 20:819–827.
 12. Li, Q., Withoff, S., and Verma, I.M. 2005. Inflam-
mation-associated cancer: NF-kappaB is the lynch-
pin. Trends Immunol. 26:318–325.
 13. Liu, Z.G. 2005. Molecular mechanism of TNF sig-
naling and beyond. Cell Res. 15:24–27.
 14. Tracey, K.J. 1994. Tumor necrosis factor-alpha. In 
The cytokine handbook. 2nd edition. A. Thomson, 
editor. Academic Press. London, United Kingdom. 
289–304.
 15. Pfeffer, K., et al. 1993. Mice deficient for the 55 
kd tumor necrosis factor receptor are resistant to 
endotoxic shock, yet succumb to L. monocytogenes 
infection. Cell. 73:457–467.
 16. Mori, R., Kondo, T., Oshima, T., Ishida, Y., and 
Mukaida, N. 2002. Accelerated wound healing 
in tumor necrosis factor receptor p55-deficient 
mice with reduced leukocyte infiltration. FASEB J. 
16:963–974.
 17. Bazzoni, F., and Beutler, B. 1996. The tumor necro-
sis factor ligand and receptor families. N. Engl. J. 
Med. 334:1717–1725.
 18. Senzer, N., et al. 2004. TNFerade biologic, an aden-
ovector with a radiation-inducible promoter, carry-
ing the human tumor necrosis factor alpha gene: a 
phase I study in patients with solid tumors. J. Clin. 
Oncol. 22:592–601.
 19. Kitakata, H., et al. 2002. Essential roles of tumor 
necrosis factor receptor p55 in liver metastasis of 
intrasplenic administration of colon 26 cells. Can-
cer Res. 62:6682–6687.
 20. Tomita, Y., et al. 2004. Spontaneous regression of 
lung metastasis in the absence of tumor necrosis 
factor receptor p55. Int. J. Cancer. 112:927–933.
 21. Moore, R.J., et al. 1999. Mice deficient in tumor 
necrosis factor-α are resistant to skin carcinogen-
esis. Nat. Med. 5:828–831.
 22. Liu, R., Bal, H.S., Desta, T., Behl, Y., and Graves, 
D.T. 2006. Tumor necrosis factor-α mediates dia-
betes-enhanced apoptosis of matrix-producing 
cells and impairs diabetic healing. Am. J. Pathol. 
168:757–764.
 23. Shiratori, Y., et al. 1994. Modulation of KC/gro pro-
tein (interleukin-8 related protein in rodents) release 
from hepatocytes by biologically active mediators. 
Biochem. Biophys. Res. Commun. 203:1398–1403.
 24. Marra, F., Valente, A.J., Pinzani, M., and Abboud, 
H.E. 1993. Cultured human liver fat-storing cells 
produce monocyte chemotactic protein-1. Regula-
tion by proinflammatory cytokines. J. Clin. Invest. 
92:1674–1680.
 25. Iniguez, M.A., Rodriguez, A., Volpert, O.V., Fresno, 
M., and Redondo, J.M. 2003. Cyclooxygenase-2: a 
therapeutic target in angiogenesis. Trends Mol. Med. 
9:73–78.
 26. Castellone, M.D., Teramoto, H., Williams, B.O., 
Druey, K.M., and Gutkind, J.S. 2005. Prostaglan-
din E2 promotes colon cancer cell growth through 
a Gs-axin-β-catenin signalling axis. Science. 
310:1504–1510.
 27. Berezowski, K., Stastny, J.F., and Kornstein, M.J. 
1996. Cytokeratins 7 and 20 and carcinoembryon-
ic antigen in ovarian and colonic carcinoma. Mod. 
Pathol. 9:426–429.
 28. Takahashi, M., and Wakabayashi, K. 2004. Gene 
mutations and altered gene expression in azoxy-
methane-induced colon carcinogenesis in rodents. 
Cancer Sci. 95:475–480.
 29. Hanauer, S.B. 2004. Medical therapy for ulcerative 
colitis 2004. Gastroenterology. 126:1582–1592.
 30. Rutgeerts, P., et al. 2005. Infliximab for induction 
and maintenance therapy for ulcerative colitis.  
N. Engl. J. Med. 353:2462–2476.
 31. Takayama, T., et al. 2001. Analysis of K-ras, APC, 
and beta-catenin in aberrant crypt foci in sporadic 
adenoma, cancer, and familial adenomatous pol-
yposis. Gastroenterology. 121:599–611.
 32. Babbar, N., and Casero, R.A., Jr. 2006. Tumor 
necrosis factor-α increases reactive oxygen spe-
cies by inducing spermidine oxidase in human 
lung epithelial cells: a potential mechanism for 
inflammation-induced carcinogenesis. Cancer Res. 
66:11125–11130.
 33. Yan, B.Y., et al. 2006. Tumor necrosis factor-α is a 
potent endogenous mutagen that promotes cellu-
lar transformation. Cancer Res. 66:11565–11570.
 34. Scott, K.A., et al. 2003. An anti-tumor necrosis fac-
tor-α antibody inhibits the development of experi-
mental skin tumors. Mol. Cancer Ther. 2:445–451.
 35. Bergers, G., and Benjamin, L.E. 2003. Tumorigen-
esis and the angiogenic switch. Nat. Rev. Cancer. 
3:401–410.
 36. Yoshida, S., et al. 1997. Involvement of interleukin-8, 
vascular endothelial growth factor, and basic 
fibroblast growth factor in tumor necrosis fac-
tor alpha-dependent angiogenesis. Mol. Cell. Biol. 
17:4015–4023.
 37. Leibovich, S.J., et al. 1987. Macrophage-induced 
angiogenesis is mediated by tumour necrosis fac-
tor-α. Nature. 329:630–632.
 38. Lin, E.Y., et al. 2006. Macrophages regulate the 
angiogenic switch in a mouse model of breast can-
cer. Cancer Res. 66:11238–11246.
 39. Nozawa, H., Chiu, C., and Hanahan, D. 2006. Infil-
trating neutrophils mediate the initial angiogenic 
switch in a mouse model of multistage carcinogen-
esis. Proc. Natl. Acad. Sci. U. S. A. 103:12493–12498.
 40. Bernardini, G., et al. 2003. Analysis of the role of 
chemokines in angiogenesis. J. Immunol. Methods. 
273:83–101.
 41. Kune, G.A., Kune, S., and Watson, L.F. 1988. 
Colorectal cancer risk, chronic illnesses, opera-
tions, and medications: case control results from 
research article
570	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 118   Number 2   February 2008
the Melbourne colorectal cancer study. Cancer Res. 
48:4399–4404.
 42. Thun, M.J., Nanboodiri, M.M., and Heath, C.W. 
1991. Aspirin use and reduced risk of fatal colon 
cancer. N. Engl. J. Med. 325:1593–1596.
 43. Sano, H., et al. 1995. Expression of cyclooxygenase-1 
and -2 in human colorectal cancer. Cancer Res. 
55:3785–3789.
 44. Oshima, M., et al. 2002. Suppression of intestinal 
polyposis in ApcΔ716 knockout mice by inhibition 
of cyclooxygenase 2 (COX-2). Cell. 87:803–809.
 45. Sonoshita, M., et al. 2001. Acceleration of intesti-
nal polyposis through prostaglandin receptor EP2 
in ApcΔ716 knockout mice. Nat. Med. 7:1048–1051.
 46. Seno, H., et al. 2002. Cyclooxygenase-2 and pros-
taglandin E2 receptor EP2-dependent angiogen-
esis in ApcΔ716 mouse intestinal polyps. Cancer Res. 
62:506–511.
 47. Mutoh, M., et al. 2002. Involvement of prostaglan-
din E receptor subtype EP4 in colon carcinogenesis. 
Cancer Res. 62:28–32.
 48. Hull, M.A., Tisbury, A., Scott, N., Bonifer, C., and 
Coletta, P.L. 1999. Cyclooxygenase-2 is up-regu-
lated and localized to macrophages in the intestine 
of Min mice. Brit. J. Cancer. 79:1399–1405.
 49. Bamba, H., et al. 1999. High expression of 
cyclooxygenase-2 in macrophages of human colon-
ic adenoma. Int. J. Cancer. 83:470–475.
 50. Wang, D., et al. 2004. Prostaglandin E2 promotes 
colorectal adenoma growth via transactivation 
of the nuclear peroxisome proliferators-activated 
receptor δ. Cancer Cell. 6:285–295.
 51. Pai, R., Nakamura, T., Moon, W.S., and Tarnawski, 
A.S. 2003. Prostaglandins promote colon cancer cell 
invasion; signaling by cross-talk between two distinct 
growth factor receptors. FASEB J. 17:1640–1647.
 52. Shao, J., Jung, C., Liu, C., and Sheng, H. 2005. Pros-
taglandin E2 stimulates the β-catenin/T cell fac-
tor-dependent transcription in colon cancer. J. Biol. 
Chem. 280:26565–26572.
 53. Botsios, C. 2005. Safety of tumour necrosis factor 
and interleukin-1 blocking agents in rheumatic 
diseases. Autoimmun. Rev. 4:162–170.
 54. Fujioka, N., et al. 1995. Preparation of specific 
antibodies against murine IL-1ra and the estab-
lishment of IL-1ra as an endogenous regulator 
of bacteria-induced fulminant hepatitis in mice. 
J. Leukoc. Biol. 58:90–98.
